secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-107154
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026
-------------------------------------------------------------------------------

- Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
- Cash and marketable securities $505.4M; raised $218.5M in public offering.
- Phase 3 OPERA-01 top-line data expected fall 2026; Phase 1b/2 with Pfizer atirmociclib initiated.
- OP-3136 initial clinical data expected Q2 2026; commercial launch prep for potential late 2027 approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/0001193125-26-107154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-107154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer